“We believe this vaccine candidate can make a significant contribution to the ongoing fight against Covid-19. It will move to phase 3” clinical trials “as soon as possible, to achieve our goal of making it available by the end of the year.” This was stated by Roger Connor, president of GSK Vaccines, on the occasion of the announcement of the positive clinical phase 2 data of the vaccine co-developed by the British GlaxoSmithKline and the French Sanofi. The results communicated by the two groups show “the potential of this protein-based adjuvanted vaccine candidate in the broader context of the pandemic – underlines Connor – including the need to address” Sars-CoV-2 “variants and predict doses. booster “.” Our Phase 2 data confirms the potential of this vaccine to play a role in addressing the ongoing global public health crisis, as we know more products will be needed, especially as “viral” variants continue to emerging and increasing the need for effective and booster vaccines that can be stored at normal temperatures, ”says Thomas Triomphe, executive vice president and global head of Sanofi Pasteur. “With these favorable results – he adds – we are ready to move to a global Phase 3 efficacy study. We look forward to producing additional data and working with our partners around the world to make our vaccine available. as quickly as possible “.